Name | Title | Contact Details |
---|---|---|
Gary Corona |
EVP, Chief Financial Officer | Profile |
Thierry Pieton |
Chief Financial Officer | Profile |
Yarmela Pavlovic |
Chief regulatory officer | Profile |
Sally Gardinier |
Canada Compliance Officer | Profile |
Robert Ernest |
Legal Director, Global Operations and Supply | Profile |
CommonHealth comprises Altum, Carbon, CommonHealth London, CommonHealth Paris, Conectics, Earthborn, EvoLogue, Ferguson, HLS, MBS/Vox, ProCom, Qi, Solara and Valos.
Bionix Medical Technologies has provided medical professionals with innovative medical devices since 1984. Bionix is proud to offer cerumen removal, wound care, feeding tube care, infant feeding, bolus control and nasal visualization products.
CVRx® is a private company located in Minneapolis, Minnesota. The company has developed proprietary active implantable technology for the treatment of high blood pressure, also referred to as hypertension, and heart failure. The CVRx senior management and technical team have many years of experience commercializing implantable medical devices. The company is supported by an outstanding board of directors and a world-class scientific advisory board, which includes thought leading physicians and scientists in the field of hypertension and heart failure. CVRx has developed an implantable device that is designed to treat high blood pressure and heart failure. This new device called Barostim neo™ is designed to trigger the body`s own natural blood flow regulation system to treat high blood pressure and heart failure. CVRx has a strong intellectual property foundation, which will protect this unique technology. Barostim neo is CE marked in Europe for the treatment of hypertension patients. It is also CE marked in Europe for the treatment of heart failure. This product is currently under clinical evaluation in the United States and Canada for the treatment of high blood pressure and heart failure.
Valeritas is committed to developing and commercializing innovative treatment solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of Type 2 diabetes. Valeritas` portfolio is headlined by the V-Go® disposable insulin delivery device, which is being commercialized and reimbursed in a specialty pharmaceutical model and is distributed through retail pharmacy.
E-Way International is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.